临床决策支持改善澳大利亚原住民CKD结局的成本效果
该研究从医疗付费方视角,对偏远北领地23,195名CKD风险或患者(89%为原住民)构建马尔可夫模型,评估Territory Kidney Care临床决策支持工具相比常规诊疗的成本效果。结果显示同时改善诊断与管理的情景3最具成本效果,每避免一例肾脏替代治疗和死亡的ICER分别为96,684和30,086美元,每获得QALY的ICER为3,427至63,486美元。
要点
- 同时改善CKD诊断与管理的情景3最具成本效果。
- 每获得QALY的ICER从3,427至63,486美元不等。
- 每避免一例KRT和死亡的ICER分别为96,684和30,086美元。
核心结论
- Territory Kidney Care在支持CKD早期诊断和增加已诊断患者优化管理时具有高度成本效果。
- 结果支持在CKD高负担地区通过强合作伙伴关系投资临床决策支持工具。
研究设计与样本
- 从医疗付费方视角,对2017年1月1日起偏远北领地CKD风险或患者队列构建马尔可夫队列模型。
- 使用2017-2023年6年观察性患者个体数据,外推至15年时间跨度。
- 队列共23,195人,89%为原住民,平均年龄42岁。
主要发现
- 情景3(同时改善诊断与管理)最具成本效果,每避免一例KRT的ICER为96,684美元,每避免一例死亡的ICER为30,086美元。
- 情景1(改善诊断)成本效果较低,情景2(改善管理)成本效果最低。
- 每获得QALY的ICER范围从3,427美元(情景3)到63,486美元(情景2)。
关键数值与推荐
- 情景3每避免一例KRT的ICER为96,684美元。
- 情景3每避免一例死亡的ICER为30,086美元。
- 每获得QALY的ICER:情景3为3,427美元,情景2为63,486美元。
临床怎么用
- 在CKD高负担偏远地区,可优先投资能同时促进CKD早期诊断和优化管理的临床决策支持工具。
- 实施临床决策支持工具时应建立强合作伙伴关系以改善CKD结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The Northern Territory (NT) is a hotspot for chronic kidney disease (CKD) and has a high incidence of kidney replacement therapy (KRT). The Territory Kidney Care clinical decision support (CDS) tool aims to improve diagnosis and management of CKD in remote NT, particularly among First Nations Australians. We model the cost-effectiveness of the CDS versus usual care. METHODS: Taking a health care funder perspective, we modeled a cohort of people from remote NT at risk of or with CKD, as of January 1, 2017. A Markov cohort model was developed using 6 years of observed patient-level data (2017-2023), extrapolated to a 15-year time horizon. The CDS tool was modeled to improve CKD diagnosis (scenario 1), improve management (scenario 2), or improve both diagnosis and management (scenario 3). RESULTS: The remote NT cohort consisted of 23,195 people, predominantly (89%) First Nations, with a mean age of 42 years. Scenario 3 (improved diagnosis and management) was most cost-effective at an incremental cost-effectiveness ratio (ICER) of $96,684 per patient avoiding KRT, $30,086 per patient avoiding death. Scenario 1 (improved diagnosis) was less cost-effective, and scenario 2 (improved management) was the least cost-effective. The ICER per quality-adjusted life years (QALYs) gained ranged from $3427 (scenario 3) to $63,486 (scenario 2). CONCLUSION: Territory Kidney Care is highly cost-effective when it supports early diagnosis of CKD and increases optimal management in diagnosed patients. These results support investing in CDS tools, implemented in strong partnerships, to improve outcomes in settings with a high burden of CKD.
引用
- Chen W, Howard K, Gorham G, et al. Cost-Effectiveness of Clinical Decision Support to Improve CKD Outcomes Among First Nations Australians. Kidney Int Rep. 2024. PMID: 39990899. doi:10.1016/j.ekir.2024.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。